- ISIN
- US6294441000
- CUSIP
- 629444100
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Dec 4, 2017
Highlights
- Market Cap
- $54.45M
- Enterprise Value
- $49.06M
- EPS (TTM)
- -$0.85
- Total Revenue (TTM)
- $2.29M
- Gross Profit (TTM)
- $620.00K
- EBITDA (TTM)
- -$32.60M
- Year Range
- $1.62 - $5.06
- Target Price
- $2.00
- ROA (TTM)
- -206.17%
- ROE (TTM)
- 177.63%
- Avg. Volume (1M)
- 873K
- Avg. Volume Value (1M)
- $3.39M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
NRXP Performance Chart
NRx Pharmaceuticals, Inc. (NRXP) is up 16.2% since the beginning of the year. At $3 per share, NRXP is trading 37.7% below its 52-week high of $5. Investors who bought $1,000 worth of NRXP shares 5 years ago would now be looking at an investment worth $21.
Loading charts...
Compare this symbol against anything
Returns By Period
NRx Pharmaceuticals, Inc. (NRXP) has returned 16.24% so far this year and 21.62% over the past 12 months.
NRx Pharmaceuticals, Inc.
- 1D
- 0.96%
- 1M
- -18.60%
- 6M
- 50.00%
- YTD
- 16.24%
- 1Y
- 21.62%
- 3Y*
- -7.60%
- 5Y*
- -53.93%
- 10Y*
- —
- ALL TIME*
- -32.62%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
NRXP Monthly Returns History
Based on dividend-adjusted daily data since Dec 4, 2017, NRXP's average daily return is +0.08%, while the average monthly return is +0.53%. At this rate, an investment would double in approximately 10.9 years.
Historically, 55% of months were positive and 45% were negative. The best month was Jan 2021 with a return of +140.7%, while the worst month was May 2022 at -64.1%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 6 months.
On a daily basis, NRXP closed higher 36% of trading days. The best single day was May 20, 2021 with a return of +88.0%, while the worst single day was May 26, 2022 at -58.2%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -22.51% | -11.43% | 14.52% | 39.91% | 48.32% | -7.47% | -22.98% | 16.24% | |||||
| 2025 | 37.27% | -24.83% | -9.69% | 3.41% | 24.53% | 23.48% | -17.48% | -13.75% | 42.24% | -6.06% | -20.97% | 10.61% | 23.18% |
| 2024 | -19.57% | -2.97% | 31.45% | -45.33% | 47.67% | -35.96% | -6.15% | -18.34% | -9.63% | -18.93% | -4.38% | 67.94% | -52.17% |
| 2023 | 5.41% | -12.82% | -35.38% | -11.82% | 20.44% | -30.93% | -19.32% | -24.35% | -11.89% | 25.00% | 5.85% | 33.72% | -58.56% |
| 2022 | -37.87% | 0.67% | -18.06% | -36.33% | -64.14% | 7.26% | 32.17% | -18.03% | 13.85% | 9.46% | 77.78% | -22.92% | -76.78% |
| 2021 | 140.74% | -34.44% | -8.02% | 9.26% | -43.15% | -47.18% | 30.64% | 3.43% | -40.96% | 9.28% | -34.06% | -28.44% | -80.41% |
Benchmark Metrics
NRx Pharmaceuticals, Inc. has an annualized alpha of 12.81%, beta of 0.58, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since December 04, 2017.
- This stock participated in 139.81% of S&P 500 Index downside but only -29.25% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.58 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.81%
- Beta
- 0.58
- R²
- 0.01
- Upside Capture
- -29.25%
- Downside Capture
- 139.81%
Return for Risk
Risk / Return Rank
NRXP ranks 54 for risk / return — above 54% of stocks peers on PortfoliosLab. Its historical combined result is near the middle of the peer group.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for NRx Pharmaceuticals, Inc. (NRXP) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| NRXP | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.22 | ||
| Sortino ratioReturn per unit of downside risk | -0.98 | ||
| Omega ratioGain probability vs. loss probability | 1.11 | 1.25 | -0.14 |
| Calmar ratioReturn relative to maximum drawdown | 0.32 | 2.00 | -1.69 |
| Martin ratioReturn relative to average drawdown | 0.58 | 8.49 | -7.91 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the NRx Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the NRx Pharmaceuticals, Inc. was 99.82%, occurring on Nov 14, 2024. The portfolio has not yet recovered.
The current NRx Pharmaceuticals, Inc. drawdown is 99.50%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-99.82%Nov 2024 | 3y 9mo | — | 5y 6moFeb 2021 - now | — |
-40.43%Jan 2021 | 14d | 14d | 28dDec 2020 - Jan 2021 | — |
-21.33%Jan 2021 | 3d | 3d | 6dJan 2021 - Jan 2021 | — |
-13.88%Dec 2020 | 1d | 1d | 2dDec 2020 - Dec 2020 | — |
-11.39%Jun 2020 | 1mo 27d | 5mo 17d | 7mo 14dMay 2020 - Dec 2020 | — |
Drawdown Indicators
| NRXP | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.82% | -56.78% | -43.04% |
Max Drawdown (1Y)Largest decline over 1 year | -54.22% | -9.10% | -45.12% |
Max Drawdown (3Y)Largest decline over 3 years | -83.44% | -18.90% | -64.54% |
Max Drawdown (5Y)Largest decline over 5 years | -99.35% | -25.43% | -73.92% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.50% | -1.58% | -97.92% |
Average DrawdownAverage peak-to-trough decline | -60.99% | -10.70% | -50.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 29.50% | 2.14% | +27.36% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of NRx Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how NRx Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for NRXP relative to other companies in the Biotechnology industry. Currently, NRXP has a P/S ratio of 39.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with NRXP
Add NRx Pharmaceuticals, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with NRXP